Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

FTSE 100 drops by most in three weeks as dour earnings, stronger pound weigh

Published 18/02/2021, 08:47
Updated 18/02/2021, 17:50
© Reuters. FILE PHOTO: The London Stock Exchange Group offices are seen in the City of London, Britain

By Shashank Nayar

(Reuters) - London's FTSE 100 fell on Thursday by the most in nearly three weeks as a set of glum earnings reports underscored the impact of the COVID-19 pandemic, while a stronger pound also weighed on the export-heavy index.

The blue-chip FTSE 100 closed 1.4% lower, led by declines in healthcare, energy and banking stocks, while the mid-cap index fell 1%.

Sterling edged up against both the euro and the dollar, reaching its highest in almost a year. [GBP/]

Barclays (LON:BARC) fell 4.4% after the British lender's 2020 annual profit halved.

"The company (Barclays) got the cold shoulder from the market as attention was drawn by large provisions on Covid-related bad debt and a warning of a continuing impact through the course of 2021," said Russ Mould, investment director at AJ Bell.

Meanwhile, Bank of England policymaker Michael Saunders said negative interest rates may soon be the best tool for the Bank of England, and raised the prospect of unemployment taking a long time to return to pre-pandemic levels.

England's third national COVID-19 lockdown is helping reduce infections, a study found, but the prevalence of cases remains high as Prime Minister Boris Johnson eyes a cautious route to re-opening the economy.

The FTSE 100 has recovered nearly 35% from its March 2020 lows but has been largely range-bound since the beginning of this year as weak corporate earnings undermine hopes of economic growth in the second half of the year.

Smith+Nephew fell 5.9% after warning that the impact of the pandemic is likely to continue into the first half of 2021 and posting a drop in annual trading profit.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Indivior fell 6.5% after the opioid addiction treatment maker predicted 2021 revenue would slip on a difficult first-half and posted an annual revenue decline of 18%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.